Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP1 | P53582 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 6/20 | 0.42 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | HTR1A | P08908 | 4/20 | 0.42 |
| ▸ | HTR7 | P34969 | 4/20 | 0.42 |
| ▸ | HTR2B | P41595 | 3/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | DRD3 | P35462 | 3/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.42 |
| ▸ | DDB1 | Q16531 | 3/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.40 |
| ▸ | DRD4 | P21917 | 3/20 | 0.39 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.39 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.39 |
| ▸ | S100A4 | P26447 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2909996 | 0.80 | METAP1 (0.56) | METAP1HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL7590593 | 0.72 | METAP1 (0.54) | METAP1HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL29620996 | 0.72 | METAP1 (0.58) | METAP1HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL3134915 | 0.72 | METAP1 (0.58) | METAP1HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL3276920 | 0.71 | METAP1 (0.44) | METAP1HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL31208446 | 0.70 | METAP1 (0.53) | METAP1HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL29404958 | 0.70 | METAP1 (0.56) | METAP1HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL27317325 | 0.70 | METAP1 (0.53) | METAP1HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL11563001 | 0.70 | METAP1 (0.53) | METAP1HTR2AHTR2CHTR1AHTR7 | |
| SCHEMBL30666697 | 0.70 | METAP1 (0.53) | METAP1HTR2AHTR2CHTR1AHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1425267-B1 | C2-SUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2010-06-30 | — | — | EP | disclosed |
| US-6946492-B2 | Use of C2-substituted indan-1-one systems for preparing medicaments for the treatment of obesity | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-09-20 | — | — | US | disclosed |
| US-6762326-B2 | SUCH AS 5-CHLORO-2-METHYLSULFANYLINDAN-1-ONE FOR WEIGHT CONTROL/DIETETICS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-07-13 | — | — | US | disclosed |
| EP-1425267-A2 | C2-SUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | disclosed |
| EP-1424999-A1 | USE OF C2-SUBSTITUTED INDANE-1-ONE SYSTEMS FOR PRODUCING MEDICAMENTS FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | disclosed |
| US-20030134882-A1 | Use of C2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-17 | — | — | US | disclosed |
| US-20030130345-A1 | C2-substituted idan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2003-07-10 | — | — | US | disclosed |
| WO-2003020677-A2 | C2-SUBSTITUTED INDANE-1-ONES AND THEIR DERIVATIVES, METHOD FOR THEIR PRODUCTION AND THEIR USE AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
| WO-2003020256-A1 | USE OF C2-SUBSTITUTED INDANE-1-ONE SYSTEMS FOR PRODUCING MEDICAMENTS FOR THE PROPHYLAXIS OR TREATMENT OF OBESITY | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2003-03-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134882-A1 | Use of C2-substituted indan-1-one systems for preparing medicaments for the prophylaxis or treatment of obesity | GPR119, CPT1A, IDO1 | METAP1 169/4885HTR2A 1416/4885HTR2C 1197/4885 |
| US-20030130345-A1 | C2-substituted idan-1-ones and their derivatives, processes for their preparation and their use as pharmaceuticals | SLC10A2, ANO1, CYP1B1 | METAP1 2696/4885HTR2A 1468/4885HTR2C 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.